Based on brand-sponsored clinical trials, as reported by Peter Thomas Roth
In March 2024 the FDA approved semaglutide to help to lower the risk of cardiovascular death, heart attack and stroke in overweight or obese patients (Patchen)
20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group
Overall impact on social life "I feel like my relationship with my husband is stronger than ever," said Melissa, "With my focus not being on food, I am more apt to gather with family and friends without worrying about what Im going to eat or what my next meal will be." - Melissa Daniella remarked that increased mood has allowed for more social interactions, which in turn strengthens those relationships and helps her feel more socially connected
The Current State of GLP-1 Drugs 2023 research from IQVIA has shown that demand for GLP-1 drugs has accelerated since early 2020, corresponding to the launches of Ozempic, Wegovy and Mounjaro variations
It's difficult to discern which option may be the best for you
